Anixa Biosciences(ANIX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ANIX Anixa Biosciences

Market Closed 04-11 16:00:00 EDT

2.58

-0.08

-3.01%

盘后2.46

-0.12-4.65%

18:51 EDT

High2.74	Low2.55	Vol62.85K
Open2.70	D1 Closing2.66	Amplitude7.14%
Mkt Cap83.06M	Tradable Cap78.67M	Total Shares32.19M
T/O164.27K	T/O Rate0.21%	Tradable Shares30.49M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"ANIX","market":"US","secType":"STK","nameCN":"Anixa Biosciences","latestPrice":2.58,"timestamp":1744401600000,"preClose":2.66,"halted":0,"volume":62850,"hourTrading":{"tag":"盘后","latestPrice":2.46,"preClose":2.58,"latestTime":"18:51 EDT","volume":132,"amount":325.03,"timestamp":1744411880020},"delay":0,"floatShares":30491438,"shares":32194862,"eps":-0.393566,"marketStatus":"Market Closed","change":-0.08,"latestTime":"04-11 16:00:00 EDT","open":2.7,"high":2.74,"low":2.55,"amount":164269.002375,"amplitude":0.071429,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.393566,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1744617600000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":2.66,"preHourTrading":{"tag":"盘前","latestPrice":2.7,"preClose":2.66,"latestTime":"09:25 EDT","volume":100,"amount":270,"timestamp":1744377900031},"postHourTrading":{"tag":"盘后","latestPrice":2.46,"preClose":2.58,"latestTime":"18:51 EDT","volume":132,"amount":325.03,"timestamp":1744411880020},"volumeRatio":1.020817772089778,"impliedVol":0.9541,"impliedVolPercentile":0.5139},"requestUrl":"/m/hq/s/ANIX","defaultTab":"news","newsList":[{"id":"2526812312","title":"Anixa Biosciences Shares Rise After Notice of Patent Allowance for Breast Cancer Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2526812312","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526812312?lang=en_us&edition=full_marsco","pubTime":"2025-04-10 02:46","pubTimestamp":1744224402,"startTime":"0","endTime":"0","summary":"Anixa Biosciences  shares were up over 10% in recent Wednesday trading after the company said it received a notice of allowance from the US Patent and Trademark Office for its breast cancer vaccine technology.The patent, licensed exclusively from Cleveland Clinic, broadens the scope of immunogenic compositions in the vaccine. It covers methods of immunizing patients using a protein found in breast tissue and certain breast cancers, Anixa said Wednesday.Price: 2.63, Change: +0.25, Percent Change: +10.29","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","ANIX"],"gpt_icon":0},{"id":"2526236551","title":"BRIEF-Anixa Biosciences Receives Notice Of Allowance From U.S. Patent And Trademark Office","url":"https://stock-news.laohu8.com/highlight/detail?id=2526236551","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526236551?lang=en_us&edition=full_marsco","pubTime":"2025-04-09 20:21","pubTimestamp":1744201319,"startTime":"0","endTime":"0","summary":"BRIEF-Anixa Biosciences Receives Notice Of Allowance From U.S. Patent And Trademark OfficeApril 9 (Reuters) - Anixa Biosciences Inc ANIX.O:ANIXA BIOSCIENCES RECEIVES NOTICE OF ALLOWANCE FROM U.S. PATE","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250409:nTUA2Z1CDC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ANIX"],"gpt_icon":0},{"id":"2526682663","title":"Anixa Biosciences Receives Notice of Allowance From U.S. Patent and Trademark Office for Patent Covering Breast Cancer Vaccine Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2526682663","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526682663?lang=en_us&edition=full_marsco","pubTime":"2025-04-09 20:00","pubTimestamp":1744200005,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250409:nTUA2Z1CDC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ANIX"],"gpt_icon":0},{"id":"2526836558","title":"Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for Patent Covering Breast Cancer Vaccine Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2526836558","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526836558?lang=en_us&edition=full_marsco","pubTime":"2025-04-09 20:00","pubTimestamp":1744200000,"startTime":"0","endTime":"0","summary":"Patent Broadens Immunogenic Compositions for Preventive Vaccine Approach. About Anixa Biosciences, Inc. Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell  technology. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against \"retired\" proteins that have been found to be expressed in certain forms of cancer. These vaccines were developed at Cleveland Clinic and licensed to Anixa Biosciences. Cleveland Clinic is entitled to roya","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/anixa-biosciences-receives-notice-allowance-120000401.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/anixa-biosciences-receives-notice-allowance-120000401.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ANIX"],"gpt_icon":0},{"id":"2526368704","title":"EXCLUSIVE: Anixa Biosciences Receives Key US Patent Nod For Breast Cancer Vaccine Patent","url":"https://stock-news.laohu8.com/highlight/detail?id=2526368704","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526368704?lang=en_us&edition=full_marsco","pubTime":"2025-04-09 19:45","pubTimestamp":1744199131,"startTime":"0","endTime":"0","summary":"On Wednesday, the United States Patent and Trademark Office  issued a Notice of Allowance for a new patent related to Anixa Biosciences, Inc.'s  breast cancer vaccine technology.Cleveland Clinic has exclusively licensed the patent and others related to this technology to Anixa Biosciences. The patent will expand the scope of immunogenic compositions utilized in Anixa's breast cancer vaccine.Also Read: EXCLUSIVE: Anixa Biosciences Inks Letter of Intent with Austria-Based VERDI Solutions To Develop AI-Guided Personalized Cancer Vaccines. Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences, stated, \"This patent strengthens our intellectual property portfolio and highlights the novelty of our breast cancer vaccine. Our intellectual property portfolio includes multiple issued and pending patents in the U.S. and international jurisdictions.\". In March, the USPTO issued a Notice of Allowance for a key patent application coveringAnixa Biosciences ovarian cancer vaccine technology.The patent ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exclusive-anixa-biosciences-receives-key-114531091.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ANIX","BK4139"],"gpt_icon":0},{"id":"2522387645","title":"Anixa Biosciences Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2522387645","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522387645?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 19:33","pubTimestamp":1742988780,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ANIX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 26, 2025 07:33 ET (11:33 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANIX"],"gpt_icon":0},{"id":"2522074793","title":"Anixa Enters Letter of Intent to Develop Verdi's AI-Guided Cancer Vaccines","url":"https://stock-news.laohu8.com/highlight/detail?id=2522074793","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522074793?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 21:36","pubTimestamp":1742909760,"startTime":"0","endTime":"0","summary":"Anixa Biosciences  said Tuesday it has entered into a letter of intent with Verdi Solutions to develop artificial intelligence-guided peptide vaccines, tailored to individual cancer patients.Under the letter of intent, Anixa has a six-month exclusive right to finalize a transaction for the research, development, and commercialization of Verdi's cancer vaccines.Anixa and Verdi are targeting to start clinical trials for personalized vaccines in the US, the biotechnology company said.Verdi is also developing off-the-shelf cancer vaccines, combined with companion diagnostics, Anixa said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","ANIX"],"gpt_icon":0},{"id":"2522020238","title":"BRIEF-Anixa Biosciences Enters Letter of Intent with VERDI Solutions to Develop Artificial Intelligence-Guided Personalized and Off-the-Shelf Cancer Vaccines","url":"https://stock-news.laohu8.com/highlight/detail?id=2522020238","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522020238?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 20:24","pubTimestamp":1742905488,"startTime":"0","endTime":"0","summary":"BRIEF-Anixa Biosciences Enters Letter of Intent with VERDI Solutions to Develop Artificial Intelligence-Guided Personalized and Off-the-Shelf Cancer VaccinesMarch 25 (Reuters) - Anixa Biosciences Inc ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nFWN3Q818O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ANIX"],"gpt_icon":0},{"id":"2522022678","title":"Anixa Biosciences Enters Letter of Intent With Verdi Solutions to Develop Artificial Intelligence-Guided Personalized and off-the-Shelf Cancer Vaccines","url":"https://stock-news.laohu8.com/highlight/detail?id=2522022678","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522022678?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 20:02","pubTimestamp":1742904121,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nFWN3Q818O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ANIX"],"gpt_icon":0},{"id":"2522022572","title":"EXCLUSIVE: Anixa Biosciences Inks Letter of Intent with Austria-Based VERDI Solutions To Develop AI-Guided Personalized Cancer Vaccines","url":"https://stock-news.laohu8.com/highlight/detail?id=2522022572","media":"Benzinga","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522022572?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 19:51","pubTimestamp":1742903476,"startTime":"0","endTime":"0","summary":"On Tuesday, Anixa Biosciences, Inc.  entered into a letter of intent with VERDI Solutions GmbH to develop personalized and off-the-shelf peptide vaccines for cancer patients.VERDI Solutions, headquartered in Vienna, Austria, is developing personalized cancer treatment by integrating artificial intelligence  and advanced cloud computing to accelerate the development and implementation of personalized cancer vaccines.VERDI's cloud-computing platform enables the rapid development of personalized peptide vaccines tailored to individual cancer patients. Additionally, the company is developing off-the-shelf cancer vaccines paired with companion diagnostics.Also Read: EXCLUSIVE: Anixa Biosciences Poised To Receive US Patent For Ovarian Cancer Vaccine. In some European countries, oncologists may administer personalized cancer vaccines under Individueller Heilversuch , which allows physicians to prescribe individualized treatments.Unlike clinical trials, where only a limited number of eligible ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exclusive-anixa-biosciences-inks-letter-115116246.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"EXCLUSIVE: Anixa Biosciences Inks Letter of Intent with Austria-Based VERDI Solutions To Develop AI-Guided Personalized Cancer Vaccines","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ANIX"],"gpt_icon":0},{"id":"2522813026","title":"Anixa Biosciences Price Target Maintained With a $7.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2522813026","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522813026?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 19:23","pubTimestamp":1742901780,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ANIX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 25, 2025 07:23 ET (11:23 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANIX"],"gpt_icon":0},{"id":"2522044316","title":"Anixa Biosciences: Buy Rating Affirmed Amid Patent Approval and Clinical Trial Advancements","url":"https://stock-news.laohu8.com/highlight/detail?id=2522044316","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522044316?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 18:16","pubTimestamp":1742897812,"startTime":"0","endTime":"0","summary":"Analyst Yi Chen from H.C. Wainwright reiterated a Buy rating on Anixa Biosciences (ANIX – Research Report) and keeping the price target at $7.00. Y...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/anixa-biosciences-buy-rating-affirmed-amid-patent-approval-and-clinical-trial-advancements?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/anixa-biosciences-buy-rating-affirmed-amid-patent-approval-and-clinical-trial-advancements?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ANIX"],"gpt_icon":0},{"id":"2521723668","title":"Anixa Biosciences Receives US Patent Notice of Allowance for Potential Ovarian Cancer Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2521723668","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521723668?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 20:40","pubTimestamp":1742820007,"startTime":"0","endTime":"0","summary":"Anixa Biosciences  said Monday that it received a notice of allowance from the US Patent and Trademark Office for its patent application covering its potential ovarian cancer vaccine.The patent application includes claims related to methods for eliciting an immune response targeting the anti-Mullerian hormone receptor, type II, or AMHR2, a target for ovarian cancer prevention and treatment, Anixa said.The allowed claims include methods of administering an immunogenic composition consisting of a nucleic acid encoding the AMHR2 polypeptide, the company said.Anixa said its ovarian cancer vaccine is being developed in collaboration with the Cleveland Clinic and the National Cancer Institute.Shares of Anixa were up more than 3% in recent premarket activity.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ANIX","BK4139"],"gpt_icon":0},{"id":"2521274022","title":"BRIEF-Anixa Biosciences Receives Notice of Allowance from USPTO for Ovarian Cancer Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2521274022","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521274022?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 20:20","pubTimestamp":1742818805,"startTime":"0","endTime":"0","summary":"BRIEF-Anixa Biosciences Receives Notice of Allowance from USPTO for Ovarian Cancer VaccineMarch 24 (Reuters) - Anixa Biosciences Inc ANIX.O:ANIXA BIOSCIENCES RECEIVES NOTICE OF ALLOWANCE FROM USPTO FO","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nTUA4SCWDD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANIX","BK4139"],"gpt_icon":0},{"id":"2521747865","title":"Anixa Biosciences Receives Notice of Allowance From Uspto for Ovarian Cancer Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2521747865","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521747865?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 20:00","pubTimestamp":1742817606,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nTUA4SCWDD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ANIX"],"gpt_icon":0},{"id":"2521252016","title":"Anixa Biosciences Holds Annual Stockholder Meeting 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2521252016","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521252016?lang=en_us&edition=full_marsco","pubTime":"2025-03-22 04:54","pubTimestamp":1742590464,"startTime":"0","endTime":"0","summary":"Anixa Biosciences ( ($ANIX) ) has issued an update. On March 20, 2025, Anixa Biosciences, Inc. held its annual meeting of stockholders, where 20,69...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/anixa-biosciences-holds-annual-stockholder-meeting-2025?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/anixa-biosciences-holds-annual-stockholder-meeting-2025?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ANIX","BK4139"],"gpt_icon":0},{"id":"2521896272","title":"Anixa Biosciences Initiated at Buy by Maxim Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2521896272","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521896272?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 20:58","pubTimestamp":1742561880,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ANIX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 21, 2025 08:58 ET (12:58 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANIX","BK4139"],"gpt_icon":0},{"id":"2520552819","title":"Anixa Biosciences CEO to Present at the 2025 CAGLA NeauxCancer Conference on March 28th","url":"https://stock-news.laohu8.com/highlight/detail?id=2520552819","media":"PR Newswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520552819?lang=en_us&edition=full_marsco","pubTime":"2025-03-17 20:00","pubTimestamp":1742212800,"startTime":"0","endTime":"0","summary":"SAN JOSE, Calif., March 17, 2025 /PRNewswire/ -- Anixa Biosciences, Inc.  , a biotechnology company focused on the treatment and prevention of cancer, today announced that its Chairman and Chief Executive Officer, Dr. Amit Kumar, will be presenting at the 2025 Cancer Advocacy Group of Louisiana  NeauxCancer Conference taking place on March 27-29, 2025 at the The Roosevelt Hotel in New Orleans.Dr. Kumar's presentation will provide an overview of Anixa's pioneering programs in cancer treatment, including updates on its cutting-edge CAR-T therapy for solid tumors and its novel cancer vaccine initiatives. He will discuss the Company's latest progress in clinical development and how Anixa is advancing next-generation immunotherapies to transform cancer care.Event:2025 CAGLA NeauxCancer ConferenceDate: March 28, 2025 Time: 10:00 AM CDTLocation: The Roosevelt New Orleans Webcast: CAGLA 2025 Livestreams. The CAGLA NeauxCancer Conference is a premier gathering of leading oncology researchers, i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/anixa-biosciences-ceo-present-2025-120000560.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/anixa-biosciences-ceo-present-2025-120000560.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ANIX","BK4139"],"gpt_icon":0},{"id":"2518272677","title":"BEAM Down Despite Positive Initial Data From Genetic Disorder Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2518272677","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518272677?lang=en_us&edition=full_marsco","pubTime":"2025-03-12 00:07","pubTimestamp":1741709220,"startTime":"0","endTime":"0","summary":"Beam Therapeutics Inc. BEAM announced positive initial safety and efficacy data from a phase I/II study, which is evaluating its pipeline candidate, BEAM-302, for treating patients with alpha-1 antitrypsin deficiency .Currently, there are no approved curative treatments for the given indication.Data from the study showed that treatment with a single dose of BEAM-302 demonstrated durable, dose-dependent increases in total and functional alpha-1 antitrypsin . Also, new production of corrected protein  and decreases in toxic mutant Z-AAT were observed in circulation across the initial three doses.All three patients treated with BEAM-302  achieved a mean total AAT of 12.4M at day 28, exceeding the 11M protective therapeutic threshold. Also, treatment with BEAM-302  reduced mutant Z-AAT up to 78%.The initial safety finding suggests that treatment with BEAM-302 was well tolerated across all dose levels, leading to durable dose-dependent correction of the disease-causing mutation.Despite the ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/beam-down-despite-positive-initial-160700470.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","BK4566","BK4160","IE0002270589.USD","AAT","BK4139","BK4588","BK4505","IE00B7SZLL34.SGD","BMRN","BK4556","BEAM","IE00B19Z3581.USD","IE00B19Z3B42.SGD","BK4535","XNCR","ANIX","BK4611"],"gpt_icon":0},{"id":"2518271386","title":"Is Gilead Sciences (GILD) Stock Outpacing Its Medical Peers This Year?","url":"https://stock-news.laohu8.com/highlight/detail?id=2518271386","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518271386?lang=en_us&edition=full_marsco","pubTime":"2025-03-10 21:40","pubTimestamp":1741614010,"startTime":"0","endTime":"0","summary":"For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Gilead Sciences  is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole?Let's take a closer look at the stock's year-to-date performance to find out.Gilead Sciences is a member of our Medical group, which includes 1012 different companies and currently sits at #4 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Gilead Sciences is currently sporting a Zacks Rank of #2 .Gilead Sciences, Inc.  : Free Stock Analysi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gilead-sciences-gild-stock-outpacing-134010049.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B7SZLL34.SGD","BK4566","LU0289739699.SGD","IE00BSNM7G36.USD","BK4583","ANIX","GILD","IE00B19Z3581.USD","BK4578","LU0320765992.SGD","BK4568","LU1585245621.USD","LU0234570918.USD","LU2089984988.USD","IE00BZ1G4Q59.USD","LU0058720904.USD","BK4550","LU1430594728.SGD","LU2468319806.SGD","BK4139","LU1839511570.USD","LU0109394709.USD","LU1066053197.SGD","IE00B3T34201.USD","BK4532","LU1066051498.USD","LU2087621335.USD","IE00B19Z3B42.SGD","BK4588","LU1571399168.USD","IE0002270589.USD","LU0889565916.HKD","BK4585","IE00BKVL7J92.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.anixa.com","stockEarnings":[{"period":"1week","weight":0.0198},{"period":"1month","weight":-0.0373},{"period":"3month","weight":0.1467},{"period":"6month","weight":-0.1429},{"period":"1year","weight":-0.1988},{"period":"ytd","weight":0.1121}],"compareEarnings":[{"period":"1week","weight":0.0567},{"period":"1month","weight":-0.0446},{"period":"3month","weight":-0.0802},{"period":"6month","weight":-0.0787},{"period":"1year","weight":0.0308},{"period":"ytd","weight":-0.089}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain viral protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was founded in 1982 and is based in San Jose, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.8,"avgChangeRate":0.159061},{"month":2,"riseRate":0.3,"avgChangeRate":-0.059165},{"month":3,"riseRate":0.2,"avgChangeRate":-0.066814},{"month":4,"riseRate":0.3,"avgChangeRate":-0.030101},{"month":5,"riseRate":0.444444,"avgChangeRate":-0.086836},{"month":6,"riseRate":0.333333,"avgChangeRate":0.021834},{"month":7,"riseRate":0.777778,"avgChangeRate":0.110128},{"month":8,"riseRate":0.6,"avgChangeRate":0.009264},{"month":9,"riseRate":0.6,"avgChangeRate":0.332939},{"month":10,"riseRate":0.3,"avgChangeRate":0.009882},{"month":11,"riseRate":0.3,"avgChangeRate":-0.022543},{"month":12,"riseRate":0.4,"avgChangeRate":-0.048918}],"exchange":"NASDAQ","name":"Anixa Biosciences","nameEN":"Anixa Biosciences"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.4","shortVersion":"4.32.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Anixa Biosciences(ANIX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Anixa Biosciences(ANIX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Anixa Biosciences,ANIX,Anixa Biosciences股票,Anixa Biosciences股票老虎,Anixa Biosciences股票老虎国际,Anixa Biosciences行情,Anixa Biosciences股票行情,Anixa Biosciences股价,Anixa Biosciences股市,Anixa Biosciences股票价格,Anixa Biosciences股票交易,Anixa Biosciences股票购买,Anixa Biosciences股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Anixa Biosciences(ANIX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Anixa Biosciences(ANIX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction